SLC13A2

Across TCGA pan-cancer cohorts, SLC13A2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SLC13A2 data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher SLC13A2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated SLC13A2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

UCEC, STAD, and READ are the cancer types where SLC13A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.968	0.623	.007	18	view →
STAD	OS	Median	III,IV	0.003	0.630	<.001	17	view →
READ	DFS	Median	II,III,IV	0.336	0.816	.032	9	view →
BLCA	OS	Median	III,IV	0.172	0.579	.015	9	view →
ACC	DFS	Median	All	0.089	0.666	.017	6	view →
SKCM	DFS	Median	IV	1.000	0.201	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SLC13A2–UCEC (DFS)

Open the UCEC breakdown →